2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5888 A genome-scale in vivo transcription factor screen identifies an unexpected developmental factor that reprograms CAR-T cells for durable persistence without antigen-independent growth

xiaoyu zhou, yixuan zhou2, aijun ti3, lina zhou4, tianying chen5, Xu Feng6, yuan liu7, Jianxiang Wang Sr, MD, PhD8, george church9, Luhan Yang, PhD10
1 Qihan Biotechnology, Hangzhou, China
2 Qihan Biotechnology, Hangzhou, China
3 Qihan Biotechnology, Hangzhou, China
4 Qihan Biotechnology, Hangzhou, China
5 Qihan Biotechnology, Hangzhou, China
6 Qihan Biotechnology, Hangzhou, China
7 Qihan Biotechnology, Hangzhou, China
8 Institute of Hematology & Blood Diseases Hospital, CAMS/PUMC, tianjing, China
9 Department of Genetics, Harvard Medical School, boston, United States
10 Qihan Biotechnology, Hangzhou, China

Background: CAR-T therapy is limited by exhaustion and loss of persistence under chronic antigen exposure. Transcription factors coordinate T-cell differentiation, effector function, and persistence. Most of the TFs capable of conferring durable persistence have been identified largely, through candidate-driven studies constrained by existing knowledge of mature T-cell biology. Systematic, genome-scale surveys remain limited, and many functional screens are conducted in vitro, where the metabolic, spatial, and antigenic pressures that drive CAR-T failure in vivo may not be fully recapitulated. We therefore screened a near-comprehensive human transcription-factor library in parallel in vitro and in vivo, reasoning that an unbiased approach would uncover regulators outside the current canon — including factors not normally expressed in peripheral T cells.

Methods: We used the barcoded MORF lentiviral library encoding 1,836 human TFs (3,548 isoform barcodes) to transduce CAR T cells at MOI 0.3 with puromycin selection; cells were cryopreserved as Day 0 input. In vitro, cells underwent repeated Nalm6 stimulation without exogenous cytokines. In vivo, the library was adoptively transferred into immunodeficient mice bearing established Nalm6 leukemia, with CAR-T recovery from bone marrow, spleen, and blood. Hits were defined by enrichment over Day 0. The lead TF was individually overexpressed and benchmarked against established persistence-enhancing regulators across multiple donors; mechanism was interrogated by transcriptomic and chromatin accessibility profiling, and transformation risk was assessed by long-term culture in the absence of antigen and cytokine support.

Results:

Genome-scale screening identifies master regulators of in vivo persistence. The in vitro and in vivo arms yielded 11 and 12 significantly enriched TFs with three enriched in both. Dual-arm hits were dominated by regulators of developmental fate rather than known effector or memory TFs. Multiple paralogs within one TF family were independently enriched, most strongly in vivo, and consistently reproduced across independent replicates, supporting a shared regulatory program and providing internal validation beyond a single-gene hit. The lead factor is a developmental TF detected in thymic T cells but not in peripheral T cells. Its enforced re-expression remodeled chromatin accessibility at stemness-associated loci while attenuating accessibility at exhaustion-associated regions; transcriptionally, cells acquired a memory-like signature with enhanced metabolic fitness. These changes were established prior to antigen encounter and reinforced under repeated stimulation, positioning it as a reprogramming factor rather than a conventional persistence enhancer. Superior efficacy under high-tumor-burden rechallenge. TF-expressing CAR-T cells achieved higher peak expansion and superior tumor control than established controls. Following rechallenge at 4 times the initial tumor burden, controls relapsed within 2 weeks, whereas TF-expressing cells maintained tumor control through Day 105 with all mice tumor-free; a single transient relapse subsequently cleared. In vitro, they outperformed controls across serial stimulation, with a stronger memory phenotype and greater metabolic fitness. Enhanced function without autonomous growth. Given that enforced expression of a developmental TF raises a transformation concern, we tested this directly: in the absence of antigen and cytokine support, TF-expressing cells showed no antigen- or cytokine-independent proliferation and did not acquire growth-factor-autonomous survival during extended culture. Functional enhancement was thus strictly antigen-dependent.

Conclusions: An unbiased, genome-scale, in vivo screen identified a developmental TF, detected in thymic but not in peripheral T cells, that enhanced CAR-T-cell persistence and antitumor efficacy. Convergent enrichment of multiple paralogs within the same TF family across independent replicates supports a shared developmental regulatory program. Re-expression of the lead TF reprograms CAR-T cells toward a memory-like, exhaustion-resistant state, yielding durable control through high-dose rechallenge without conferring antigen- or cytokine-independent growth. This defines a developmental reprogramming strategy — distinct from amplifying existing memory programs — for engineering durable CAR-T cells across hematologic malignancies, solid tumors, and autoimmune disease.

Luhan Yang, PhD: No relevant conflicts of interest to declare.